Seeking AlphaCodex · 实盘不做把握 4/10
北京时间·🕒 发布 02:45:14时区推断·⟳ 抓取 02:45:25·⚡ 决策 08-04 12:02:00 +9h16m·84.7 天前
Seaport Therapeutics二季度GAAP EPS为-1.78美元且净亏损扩大
二季度净亏损从1510万美元扩大至6260万美元，GAAP EPS为-1.78美元，但公司仍称4.273亿美元现金可支持当前计划至2029年。
📄 原文Seeking Alpha↗ 原文
Seaport Therapeutics, Inc. GAAP EPS of -$1.78
- Seaport Therapeutics, Inc. press release (SPTX): Q2 GAAP EPS of -$1.78. - Net loss was $62.6 million for the second q…
不做 Seaport Therapeutics（SPTX.US）
研发型生物科技财报亏损扩大但现金可用至2029年，缺少一致预期差或管线催化；不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- Seeking Alpha转述公司二季度EPS、净亏损和现金 runway。
关键理由
- 二季度净亏损从1510万美元扩大至6260万美元，GAAP EPS为-1.78美元，但公司仍称4.273亿美元现金可支持当前计划至2029年。
主要风险
- 缺少一致预期与管线里程碑对照，单看研发型亏损扩大不足以形成可执行多空边际。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 420 字
- Seaport Therapeutics, Inc. press release (SPTX): Q2 GAAP EPS of -$1.78.
- Net loss was $62.6 million for the second quarter of 2026, as compared to a net loss of $15.1 million for the second quarter of 2025.
- Cash Position: Cash, cash equivalents, and investments totaled $427.3 million as of June 30, 2026. Seaport expects its cash, cash equivalents, and investments to support its current operating plans into 2029.
- Net loss was $62.6 million for the second quarter of 2026, as compared to a net loss of $15.1 million for the second quarter of 2025.
- Cash Position: Cash, cash equivalents, and investments totaled $427.3 million as of June 30, 2026. Seaport expects its cash, cash equivalents, and investments to support its current operating plans into 2029.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。